trending Market Intelligence /marketintelligence/en/news-insights/trending/tr3bikckzwjcuz0bclqg1g2 content esgSubNav
In This List

Medtronic's drug-coated balloons snag US FDA approval

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet


Medtronic's drug-coated balloons snag US FDA approval

Two versions of Medtronic PLC's IN.PACT Admiral balloons to treat lesions in blocked arteries have received approval from the U.S. Food and Drug Administration.

The Dublin, Ireland company's drug-coated balloons can be used to treat 200-millimeter and 250-millimeter lesions in patients with peripheral artery disease, a buildup of fatty deposits that lead to narrowed arteries and less blood flow.

The FDA approved a 360mm version of the device in April.

In all three cases, the balloons are used in the superficial femoral artery, the main artery running through the leg and an important pathway for oxygenated blood to flow through the limb.